EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based Approach

Louis Boutin, Sabri Soussi, Angèle Garcia Lavello, Elisabeth Masson Fron, Banjamin Deniau, Matthieu Legrand, Marcel Blot-Chabaud, Stefanny Muriel Figueroa, Christos Envangelos Chadjichristos, Feriel Azibani, Fançois Dépret

Cardiorenal Medicine · 2024

DOI: 10.1159/000540845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiorenal Medicine, 2024. Verfasst von Louis Boutin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Critical Care Medicine and Burn Unit, AP-HP, Saint-Louis Hospital, DMU Parabol, FHU PROMICE, Université de Paris, Pari…. Hauptthemen laut MEDLINE: CD146 Antigen, Biomarkers, Galectin 3, Burns. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute kidney injury (AKI) and myocardial injury (MI) are severe conditions in patients with severe burn injury, and combination of both is even worst and is called the cardiorenal syndrome (CRS). Identifying a distinct cardiorenal phenotype could significantly enhance the management of these patients. Galectin-3 (Gal3) and soluble CD146 (sCD146) are biomarkers for renal and cardiac injuries. This study aims to assess the occurrence and reliability of these biomarkers in recognizing CRS in individuals who have been severely burn.

Methods

This study is a single-center prospective proof-of-concept study involving patients with severe burn injuries. Plasma samples for Gal3 and sCD146 measurements were collected daily during the initial 7 days following admission. CRS was defined after 24 h of admission by the association of AKI stage 1 or more (KDIGO definition) and MI defined on high sensitive troponin (hsTnT) (variation >20% baseline value or absolute value >40 ng/mL).

Results

Forty patients met the inclusion criteria and were included in this study. Thirty-eight patients had CRS. The pooled values of Gal3 or combination of Gal3 and sCD146 values following 7 days after admission were associated with CRS with an odds ratio (OR) of 1.145 (95% CI: 1.081–1.211), p < 0.001, and 1.147 (95% CI: 1.085–1.212), p < 0.001, respectively. Gal3 values at admission (D0) had a predictive performance for CRS with an AUC of 0.78 (95% CI: 0.63–0.93), and this performance improved when using the combination of Gal3 and sCD146 values at admission (D0), with an AUC of 0.81 (95% CI: 0.66–0.96). Gal3 levels during the first 7 days were associated with patients experiencing AKI and no MI, with an OR of 1.129 (95% CI: 1.065–1.195), p < 0.001, and MI without AKI with an OR of 1.095 (95% CI: 1.037–1.167), p < 0.001. sCD146 alone was not associated with AKI without MI or MI without AKI and was poorly associated with CRS.

Conclusion

In severely burned patients, CRS is a frequent and severe condition. Gal3 values during the first 7 days following admission were associated with CRS. The use of sCD146 with Gal3 improved prediction performance for CRS identification. The use of such biomarkers to identify CRS is important and needs to be confirmed in other studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD146 AntigenBiomarkersGalectin 3BurnsAcute Kidney InjuryHumansMaleFemaleMiddle AgedProspective StudiesAdultMyocardial InfarctionAgedGalectinsBlood Proteins

Stichwörter der Autor:innen

Acute kidney injuryBiomarkerCardiorenal syndromeIntensive care unitSevere burn

Substanzen

CD146 AntigenBiomarkersGalectin 3LGALS3 protein, humanMCAM protein, humanGalectinsBlood Proteins

Autor:innen und Institutionen

  • Department of Anaesthesiology, Critical Care Medicine and Burn Unit, AP-HP, Saint-Louis Hospital, DMU Parabol, FHU PROMICE, Université de Paris, Paris, France.
  • INSERM, UMR 942, MASCOT: Cardiovascular Marker in Stress Condition, Lariboisière Hospital, Université de Paris, Paris, France.
  • INSERM, UMR 1155, CORAKID, Tenon Hospital, Sorbonne Université, Paris, France.
  • Department of Anesthesia and Pain Management, University Health Network (UHN), Women's College Hospital, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.
  • St Michael's Hospital, Keenan Research Centre for Biomedical Science and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Département de Biochimie et Biologie Moléculaire, Hôpitaux Lariboisière-Fernand Widal, Paris, France.

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Boutin, L., Soussi, S., Garcia Lavello, A., Masson Fron, E., Deniau, B., Legrand, M., Blot-Chabaud, M., Figueroa, S. M., Chadjichristos, C. E., Azibani, F., & Dépret, F. (2024). Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based Approach. Cardiorenal Medicine. https://doi.org/10.1159/000540845

Vancouver

Boutin L, Soussi S, Garcia Lavello A, Masson Fron E, Deniau B, Legrand M, et al. Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based Approach. Cardiorenal Medicine. 2024. doi:10.1159/000540845

BibTeX
@article{Boutin2024,
  author = {Boutin, Louis and Soussi, Sabri and Garcia Lavello, Angèle and Masson Fron, Elisabeth and Deniau, Banjamin and Legrand, Matthieu and Blot-Chabaud, Marcel and Figueroa, Stefanny Muriel and Chadjichristos, Christos Envangelos and Azibani, Feriel and Dépret, Fançois},
  title = {Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based Approach},
  journal = {Cardiorenal Medicine},
  year = {2024},
  doi = {10.1159/000540845}
}
Kostenlos starten →